公开(公告)号：KR1020130139576A

公开(公告)日：2013-12-23

申请号：KR1020120063133

申请日：2012-06-13

Applicant: 가톨릭대학교 산학협력단

Inventor： 김호연 ,  조미라 ,  이선영

IPC: A61K39/395 ,  A61P19/02 ,  A61P11/06 ,  A61P17/00

Abstract: The present invention relates to pharmaceutical uses of IL-2 and IL-2 antibody which are used for preventing or treating immune diseases caused by abnormality of immune responses and, more specifically, to a composition for preventing or treating immune diseases for elderly which includes IL-2 and IL-2 antibody. The IL-2 and IL-2 antibody according to the present invention can be effectively used as a pharmaceutical composition which can prevent or treat immune diseases in elderly such as autoimmune disease, inflammatory disease, and transplant rejection diseases which are caused by abnormal control of various immune responses by suppressing immune cells which are abnormally activated, suppressing activation of immune regulatory T cells (Treg) which controls inflammation responses, increasing expression of Foxp3 and STAT5, suppressing expression of Cebpb or IL-20, and having enhanced effects when IL-2 and IL-2 antibody are treated in elderly. Also the IL-2 and IL-2 antibody have no toxicity and side effects for medicine so that IL-2 and IL-2 antibody cab be used for inflammation diseases for long time, and have stable effects in vivo.

Abstract translation: 本发明涉及用于预防或治疗由免疫应答异常引起的免疫疾病的IL-2和IL-2抗体的药物用途，更具体地，涉及用于预防或治疗包括IL的老年人免疫疾病的组合物 -2和IL-2抗体。 根据本发明的IL-2和IL-2抗体可以有效地用作可以预防或治疗老年人免疫疾病的药物组合物，例如自身免疫性疾病，炎性疾病和移植排斥疾病，其由异常控制引起 通过抑制异常活化的免疫细胞，抑制控制炎症反应的免疫调节性T细胞（Treg）的激活，增加Foxp3和STAT5的表达，抑制Cebpb或IL-20的表达，并且当IL- 2和IL-2抗体在老年人中治疗。 此外，IL-2和IL-2抗体对于药物没有毒副作用，因此IL-2和IL-2抗体驾驶室长时间用于炎症疾病，并且在体内具有稳定的作用。

公开(公告)号：KR1020120118596A

公开(公告)日：2012-10-29

申请号：KR1020110036053

申请日：2011-04-19

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  김호연 ,  박진실 ,  임미애 ,  오혜좌 ,  유준걸 ,  변재경

IPC: A61K31/497 ,  A61K31/495 ,  A61K31/4164 ,  A61P37/00

CPC classification number: A61K31/496 ,  Y10S514/825

Abstract: PURPOSE: A composition for preventing and treating immunization diseases including nutlin-3a compound is provided to suppress the expression of IL-17 through overexpression of p53. CONSTITUTION: A composition for preventing and treating immunization diseases includes nutlin-3a compound. The nutlin-3a compound suppresses the IL-17 production. The IL-17 production suppression is completed by the overexpression of p53. The immunization disease is autoimmune disease, inflammation disease, transplantation rejection disease of cell, tissue or organ. The autoimmune disease or inflammation disease is rheumatoid arthritis, asthma], dermatitis, psoriasis, cystic fibrosis, multiple sclerosis, systemic lupus erythematosus, sjogren syndrome, hashimoto thyroiditis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, inflammatory Bowel dieseses, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary diseases(COPD), Graves disease, gastrointestinal allergies, conjunctivitis, and atherosclerosis. [Reference numerals] (AA) Producing amount of IL-17(pg/ml)

Abstract translation: 目的：提供一种预防和治疗包括nutlin-3a化合物在内的免疫疾病的组合物，以通过p53的过表达抑制IL-17的表达。 构成：用于预防和治疗免疫疾病的组合物包括nutlin-3a化合物。 Nutlin-3a化合物抑制IL-17的产生。 IL-17产生抑制由p53的过表达完成。 免疫疾病是自身免疫性疾病，炎症疾病，细胞，组织或器官的移植排斥疾病。 自身免疫疾病或炎症疾病是类风湿性关节炎，哮喘，皮炎，牛皮癣，囊性纤维化，多发性硬化，系统性红斑狼疮，干燥综合症，麻疹甲状腺炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎，肺纤维化， 炎性肠病，自身免疫性糖尿病，糖尿病性视网膜病变，鼻炎，缺血再灌注损伤，血管成形术后再狭窄，慢性阻塞性肺疾病（COPD），格雷夫斯病，胃肠道过敏，结膜炎和动脉粥样硬化。 （标号）（AA）IL-17的产生量（pg / ml）

公开(公告)号：KR101004363B1

公开(公告)日：2010-12-28

申请号：KR1020100024700

申请日：2010-03-19

Applicant: 한국생명공학연구원 ,  가톨릭대학교 산학협력단

Inventor： 박영우 ,  조기원 ,  유석호 ,  유정 ,  윤선하 ,  박지현 ,  송은정 ,  이종호 ,  서민지 ,  조선정 ,  조미라 ,  김호연 ,  박미경 ,  오혜좌 ,  박진실 ,  우윤주

IPC: C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  A61P37/00

CPC classification number: C07K14/7151 ,  C07K14/7155 ,  C07K2319/00

Abstract: PURPOSE: A TNFR2-IL21R fusion protein as a double antagonist to TNF-alpha and IL-21 is provided to reduce inflammatory cytokine secretion and to increase anti-inflammatory cytokine secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains a fusion protein having a fragment with extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment with extracellular region of IL21R(Interleukin-21 receptor) protein or IL21R as an active ingredient. The fusion protein has an amino acid sequence of sequence number 1.

Abstract translation: 目的：提供TNFR2-IL21R融合蛋白作为TNF-α和IL-21的双重拮抗剂，以减少炎症细胞因子分泌和增加抗炎细胞因子分泌。 构成：用于预防和治疗自身免疫疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段和IL21R（白细胞介素-21受体）蛋白或IL21R的细胞外区域的片段的融合蛋白，作为 活性成分。 融合蛋白具有序列号1的氨基酸序列。

公开(公告)号：KR1020100067708A

公开(公告)日：2010-06-22

申请号：KR1020080126216

申请日：2008-12-12

Applicant: 가톨릭대학교 산학협력단 ,  에이치 엘 지노믹스(주)

Inventor： 김호연 ,  민준기 ,  조미라 ,  박미경 ,  오혜좌 ,  허유정 ,  박진실 ,  우윤주 ,  류종현 ,  김현규 ,  이근혁 ,  박진하 ,  곽은영

IPC: A61K36/87 ,  A61P19/10

CPC classification number: A61K36/87

Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to suppress osteoclast differentiation and to prevent and treat osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The Vitis vinifera seed extract has 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanine. A method for manufacturing the Vitis vinifera seed extract comprises: a step of adding mixture solvent of water and acetone to pulverized Vitis vinifera seed and extracting at room temperature; a step of removing acetone and suturing sodium chloride and filtering; a step of extracting the extract with acetate and concentrating; and a step of adding chloroform to the concentrate and filtering.

Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，以抑制破骨细胞分化和预防和治疗骨质疏松症。 构成：用于预防或治疗骨质疏松症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物的原花青素值（PCV）为80-130，儿茶素和（ - ）表儿茶素为30％以下，原花青素为95-105％。 葡萄种子提取物的制造方法包括：将水和丙酮的混合溶剂加入粉状葡萄种子并在室温下提取的步骤; 去除丙酮并缝合氯化钠并过滤的步骤; 用醋酸提取提取物浓缩的步骤; 以及向浓缩物中加入氯仿并过滤的步骤。

公开(公告)号：KR100601080B1

公开(公告)日：2006-07-19

申请号：KR1020040067389

申请日：2004-08-26

Applicant: 가톨릭대학교 산학협력단 ,  주식회사 다림바이오텍

Inventor： 김호연 ,  조미라 ,  김상기

IPC: A61K31/353 ,  A61K31/352

Abstract: 본 발명은 녹차의 폴리페놀 중 하나인 (-)-에피갈로카테킨 갈레이트(EGCG)를 유효성분으로 함유하는 류마티스 관절염 치료제에 관한 것이다. EGCG를 류마티스 관절염 동물모델에 1㎎ 내지 100㎎/㎏의 용량으로 투여하면, 용량 의존적으로 유의성을 지니는 류마티스 관절염 치료효과가 발명되었다.
에피갈로카테킨 갈레이트, 녹차, 류마티스 관절염, 자가면역질환, 사이토카인, T 세포, 치료제

公开(公告)号：KR1020040079393A

公开(公告)日：2004-09-14

申请号：KR1020040067389

申请日：2004-08-26

Applicant: 가톨릭대학교 산학협력단 ,  주식회사 다림바이오텍

Inventor： 김호연 ,  조미라 ,  김상기

IPC: A61K31/353 ,  A61K31/352

Abstract: PURPOSE: A composition containing epigallocatechin gallate (EGCG) as one of green tea polyphenols as an effective ingredient is provided. The EGCG controls an inflammatory reaction in the lesion area of rheumatoid arthritis and a cell-mediated immune reaction which specifically reacts with an antigen and thus has a therapeutic effect on rheumatoid arthritis. CONSTITUTION: The agent for the treatment of rheumatoid arthritis contains (-)-epigallocatechin gallate and a pharmaceutically acceptable carrier such as physiological saline. The dosage of EGCG is 1 to 100mg/kg. The EGCG is administered in the form of an EGCG-PLGA complex by impregnating into a PLGA(poly/lactide/glycolide) polymer.

Abstract translation: 目的：提供含有表没食子儿茶素没食子酸酯（EGCG）作为绿茶多酚作为有效成分的组合物。 EGCG控制类风湿性关节炎的病变区域的炎症反应和与抗原特异性反应的细胞介导的免疫反应，因此对类风湿性关节炎具有治疗作用。 构成：用于治疗类风湿关节炎的药物含有（ - ） - 表没食子儿茶素没食子酸酯和药学上可接受的载体如生理盐水。 EGCG剂量为1〜100mg / kg。 通过浸渍到PLGA（聚丙交酯/乙交酯）聚合物中，EGCG以EGCG-PLGA复合物的形式施用。